Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FHND6091 in Relapsed/Refractory Multiple Myeloma
NCT05271682Phase 1Unknown
- Sponsor
- Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
- Start
- Dec 2021
- Primary completion
- Dec 2023
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of FHND6091 in multiple myeloma (MM) (8 arms), sponsored by Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. Primary endpoint: Treatment-Emergent Adverse Events. Status: unknown.
02
Drugs
FHND6091
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05271682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05271682.